Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
2028. máj. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
2027. márc. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer. Reply.
2026. nov. 5.· The New England journal of medicine· PUBMED
Publikáció
Corrigendum to "Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients" [J. Pharmaceut. Biomed. Anal. 237 (2024) 115758].
2026. nov. 5.· Journal of pharmaceutical and biomedical analysis· PUBMED
Publikáció
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
2026. nov. 5.· The New England journal of medicine· PUBMED
Publikáció
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
2026. nov. 5.· The New England journal of medicine· PUBMED
Publikáció
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
2026. nov. 5.· The New England journal of medicine· PUBMED
Publikáció
Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency.
2026. nov. 3.· Molecular cancer therapeutics· PUBMED
Vizsgálat
[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer.
2026. nov. 1.· Clinical and translational medicine· PUBMED
Publikáció
BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer.
2026. okt. 28.· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publikáció
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.
2026. okt. 27.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
Phytochemical and biological investigation of Galium sinaicum: Cytotoxic constituents with in vitro PARP-1 inhibitory activity.
2026. okt. 24.· Fitoterapia· PUBMED
Publikáció
Functional biomarkers complementing static BRCA/HRD testing for dynamic PARP inhibitor therapy in ovarian cancer: a narrative review.
2026. okt. 13.· Frontiers in oncology· PUBMED
Publikáció
Multi-cohort screening of PANoptosis-related genes reveals PARP1 as a key target, and AZD5305 exerts anti-tumor effects in neuroblastoma.
2026. okt. 12.· Frontiers in oncology· PUBMED
Publikáció
Synthesis and Preliminary Biological Evaluation of a Structurally Modified Niraparib-Based PARP-Targeted PET Tracer for Tumor Imaging.
2026. okt. 9.· ACS omega· PUBMED
Vizsgálat
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
2026. okt. 8.· PHASE2 · RECRUITING· CTGOV
Publikáció
Discovery of Dual PARP/GPX4 Inhibitors for the Treatment of Triple-Negative Breast Cancer.
2026. okt. 8.· Journal of medicinal chemistry· PUBMED
Publikáció
A Platinum(IV)-Ursolic Acid Conjugate Overcomes Cisplatin Resistance in Ovarian Cancer by Targeting XPO1 and PARP1.
2026. okt. 8.· Journal of medicinal chemistry· PUBMED
Vizsgálat
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
2026. okt. 7.· PHASE3 · RECRUITING· CTGOV
Publikáció
PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer.
2026. okt. 7.· Journal for immunotherapy of cancer· PUBMED
Publikáció
Hybrid surgical thromboembolectomy and crossover endovascular revascularization for acute lower-limb ischemia in a patient with active ovarian cancer receiving a PARP inhibitor (fuzuloparib): a case report and literature review.
2026. okt. 7.· Frontiers in cardiovascular medicine· PUBMED
Publikáció
Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers.
2026. okt. 1.· Cancer medicine· PUBMED
Publikáció
Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
2026. okt. 1.· The Journal of clinical investigation· PUBMED
Publikáció
Long-Term Drug Screening Identifies PARP Inhibitors as Irinotecan Combination Partners in BRCA1/2-Wild-Type Pancreatic Ductal Adenocarcinoma.
2026. szept. 28.· Pharmaceuticals (Basel, Switzerland)· PUBMED
Publikáció
Inhibition of Translesion DNA Synthesis Sensitizes BRCA-Deficient Ovarian Cancer to PARP Inhibitors.
2026. szept. 28.· Cancer research· PUBMED
Publikáció
Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
2026. szept. 25.· Cancers· PUBMED
Publikáció
Hit It before It Starts: Targeting a (3 + 1) Hybrid Non-canonical G-Quadruplex to Silence PARP1 in Cancer.
2026. szept. 24.· Journal of medicinal chemistry· PUBMED
Publikáció
A retrospective analysis of adverse drug reaction case reports for PARP inhibitors: a comparative study of olaparib and niraparib.
2026. szept. 24.· Frontiers in pharmacology· PUBMED
Publikáció
FANCD2 knockdown suppresses malignant phenotypes and is associated with caspase/PARP-mediated apoptosis in NCI-H2052 pleural mesothelioma cells.
2026. szept. 23.· Frontiers in genetics· PUBMED